Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

NCT Number	NCT06375343
Lead Sponsor	Laboratorios Sophia S.A de C.V.
Conditions	Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease
Enrollment	32 participants
Start Date	2026-01-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2027-01-30 (estimated)
Updated on ClinicalTrials.gov	2025-03-19